Emergent BioSolutions (EBS) director granted 5,006 restricted stock units

Rhea-AI Filing Summary

FOWLER JOHN D JR reported acquisition or exercise transactions in this Form 4 filing.

Emergent BioSolutions Inc. director John D. Fowler Jr reported an equity award of 5,006 shares of common stock in the form of restricted stock units. The units were granted at a reference value of $8.99 per share and were issued under the company’s Stock Incentive Plan.

These 5,006 restricted stock units vest in three annual installments, beginning on the day prior to the anniversary of the grant date, assuming he continues serving the company. Each unit represents the right to receive one share of Emergent BioSolutions common stock, and Fowler now directly holds 5,006 shares following this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FOWLER JOHN D JR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,006	$8.99	$45K

Holdings After Transaction: Common Stock — 5,006 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOWLER JOHN D JR

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		5,006(1)	A	$8.99	5,006	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Emergent BioSolutions (EBS) report on this Form 4?

Emergent BioSolutions reported that director John D. Fowler Jr received 5,006 restricted stock units of common stock. These units were granted under the company’s Stock Incentive Plan and represent an equity award rather than an open-market purchase or sale of shares.

How many Emergent BioSolutions (EBS) shares were involved in John D. Fowler Jr’s award?

John D. Fowler Jr was granted 5,006 restricted stock units tied to Emergent BioSolutions common stock. Following this grant, his reported direct holdings total 5,006 shares, reflecting the entire amount associated with this equity award transaction.

What is the vesting schedule for the 5,006 restricted stock units at Emergent BioSolutions (EBS)?

The 5,006 restricted stock units vest in three annual installments. Vesting begins on the day prior to the anniversary of the grant date and continues each year, contingent on John D. Fowler Jr maintaining continuous service with Emergent BioSolutions.

How is each restricted stock unit defined in the Emergent BioSolutions (EBS) grant?

Each restricted stock unit represents the right to receive one share of Emergent BioSolutions common stock. The units are subject to adjustment under the grant agreement and vest over time, aligning director compensation with long-term company performance and service.

At what reference price were the Emergent BioSolutions (EBS) restricted stock units granted?

The 5,006 restricted stock units were granted at a reference value of $8.99 per share. This grant value helps define the size of the equity award, though the actual benefit depends on future Emergent BioSolutions common stock performance and the vesting of the units.

Under which plan were the restricted stock units for Emergent BioSolutions (EBS) director granted?

The restricted stock units granted to director John D. Fowler Jr were issued under Emergent BioSolutions’ Stock Incentive Plan. This plan provides equity-based compensation, designed to reward service and potentially align directors’ interests with longer-term company performance.